Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Bariatric surgery reduces the progression to decompensated cirrhosis and the risk for major adverse liver outcomes, such as ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Shares of Madrigal Pharmaceuticals ( MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...